Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
BioDelivery Sciences International |
---|---|
Information provided by: | BioDelivery Sciences International |
ClinicalTrials.gov Identifier: | NCT00293033 |
The purpose of this study is to evaluate the efficacy of BEMA fentanyl at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy. The standard of care for these breakthrough pain episodes is a rapid onset, short acting analgesic with minimal associated sleepiness. Oral morphine, oxycodone and hydromorphone are routinely used, but because of slow and variable oral absorption, the pain control is not the best with these products. Oral transmucosal fentanyl citrate (OTFC) has been used successfully in treating breakthrough pain episodes associated with cancer. OTFC is a lozenge of fentanyl on a stick and is administered by continuously swabbing the interior of the subject's mouth until the product is dissolved (approximately 15 to 30 minutes). The buccal route of administration avoids the delay and variability associated with oral absorption.
BioDelivery Sciences International, Inc. (BDSI) has developed BEMA (BioErodible MucoAdhesive) fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small disc that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the disc readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the disc are water soluble, so the entire dosage form dissolves within 30 minutes of application.
Condition | Intervention | Phase |
---|---|---|
Pain Cancer |
Drug: BEMA™ Fentanyl |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Factorial Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Placebo Controlled Evaluation of the Efficacy, Safety and Tolerability of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, North Carolina | |
PPD Development | |
Wilmington, North Carolina, United States, 28412 |
Study Chair: | Andrew Finn, PharmD | BioDelivery Sciences International |
Responsible Party: | BioDelivery Sciences International ( Andrew Finn, PharmD, Executive Vice President, Product Development ) |
Study ID Numbers: | FEN-201 |
Study First Received: | February 15, 2006 |
Last Updated: | January 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00293033 |
Health Authority: | United States: Food and Drug Administration |
Breakthrough Pain in Cancer Patients |
Fentanyl Pain |
Anesthetics, Intravenous Physiological Effects of Drugs Central Nervous System Depressants Anesthetics Narcotics Pharmacologic Actions Adjuvants, Anesthesia |
Sensory System Agents Anesthetics, General Therapeutic Uses Analgesics Peripheral Nervous System Agents Central Nervous System Agents Analgesics, Opioid |